T-type calcium channels inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 1, 2011, Pages 85-101

  Giordanetto, Fabrizio ^a   Knerr, Laurent ^a   Wllberg, Andreas ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Calcium channel inhibition; Cav3; Mibefradil; T type calcium channels

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CALCIUM CHANNEL T TYPE A1 ANTAGONIST; CALCIUM CHANNEL T TYPE A2 ANTAGONIST; CALCIUM CHANNEL T TYPE A8 ANTAGONIST; CALCIUM CHANNEL T TYPE P1 ANTAGONIST; CALCIUM CHANNEL T TYPE P2 ANTAGONIST; CALCIUM CHANNEL T TYPE Q3 ANTAGONIST; CALCIUM CHANNEL T TYPE Q4 ANTAGONIST; FLUNARIZINE; KYSO5001; KYSO5041; KYSO5090; MIBEFRADIL; PIMOZIDE; UNCLASSIFIED DRUG;

ARTIFICIAL HEART PACEMAKER; BINDING AFFINITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; EPILEPSY; HEART FAILURE; HUMAN; HYPERTENSION; IC 50; NEUROPATHIC PAIN; NONHUMAN; PHYSIOLOGICAL PROCESS; REVIEW; SLEEP; SLEEP DISORDER; TREATMENT RESPONSE;

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATENTS AS TOPIC;

EID: 78650468385     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.536532     Document Type: Review

References (103)

1. Brini M, Carafoli E. Calcium signalling: a historical account, recent developments and future perspectives. Cell Mol Life Sci 2000;57:354-70
2. Ertel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron 2000;25:533-5
3. Talley EM, Cribbs LL, Lee JH, et al. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci 1999;19:1895-911
4. Satoh H. Role of T-type calcium channel inhibitors in the pacemaker depolarisation in rabbit sino-atrial nodal cells. Gen Pharmacol 1995;26:581-7
5. Ono K, Iijima T. Cardiac T-type calcium channels in the heart. J Mol Cell Cardiol 2010;48:65-70
6. Kuga T, Sadoshima J, Tomoike H. Actions of calcium antagonists on two types of calcium channels in rat aorta smooth muscle cells in primary culture. Circ Res 1990;67:469-80
7. Kim D, Song I, Keum S. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha 1G T-type calcium channels. Neuron 2001;31:35-45
8. Van der Vring JA, Cleophas TJ, Van der Wall EE, et al. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel calcium channel blocker study group. Am J Ther 1999;6:229-33
9. Sen L, Smith TW. T-type calcium channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1999;75:149-55
10. Fareh S, Benardeau A, Nattel S. Differential efficacy of L-and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 2001;49:762-70
11. Uebele VN, Gotter AL, Nuss CE, et al. Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J Clin Invest 2009;119:1659-67
12. Lopez-Gonzalez I, Olamendi-Portugal T, De la Vega-Beltran JL, et al. Scorpion toxins that block T-type calcium channels in spermatogenic cells inhibit the sperm acrosome reaction. Biochem Biophys Res Commun 2003;300:408-14
13. Taylor JT, Huang L, Pottle JE, et al. Calcium signalling and T-type calcium channels in cancer cell cycling. World J Gastroentherol 2008;14:4984-91
14. Taylor JT, Huang L, Pottle JE, et al. Selective blockade of T-type calcium channels suppresses human breast cancer cell proliferation. Cancer Lett 2008;267:118-24
15. Li Y, Liu S, Le F, et al. The role of T-type calcium channels in hepatocellular carcinoma cell proliferation. Oncol Rep 2009;22:1229-35
16. Heo JH, Seo HN, Choe YJ, et al. T-type calcium channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett 2008;18:3899-901
17. Zamponi GW, Lewis RJ, Todorovic SM, et al. Role of voltage calcium channels in ascending pain pathways. Brain Res Rev 2008;60:84-9
18. Todorvic SM, Jevtovic-Todorovic V. The role of T-type calcium channels in peripheral and central pain processing. CNS Neurol Disord Drug Targets 2006;5:639-53
19. Barton ME, Eberle EL, Shannon HE. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione and Mibefradil. Eur J Pharmacol 2005;521:79-85
20. Bourinet E, Alloui A, Monteil A, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 2005;24:315-24
21. Choi S, Na HS, Kim J, et al. Attenuated pain responses in mice lacking CaV3.2 T-type channels. Genes Brain Behavior 2007;6:425-31
22. Tsakaridou E, Bertollini L, De Curtis M, et al. Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. J Neurosci 1995;15:3110-17
23. Lee J, Shin HS. T-type calcium channels and thalamocortical rhythms in sleep: a perspective from studies of T-type calcium channel knock-out mice. CNS Neurol Disord Drug Targets 2007;6:63-9
24. Traboulsie A, Chemin J, Kupfer E. T-Type Calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol Pharmacol 2006;69(6):1963-8
25. Uslaner JM, Vardigan JD, Drott JM, et al. T-type calcium channel antagonism decreases motivation for nicotine and blocks nicotine-and cue-induced reinstatement for a response previously reinforced with nicotine. Biol Physchiatry 2010;68:712-18
26. Abernethy DR. Pharmacologic and pharmacokinetic profile of Mibefradil, a T-and L-type calcium channel antagonist. Am J Cardiol 1997;80:4C-11C
27. Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, et al. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 1999;55:559-65
28. Jimenez C, Bourinet E, Leuranguer V, et al. Determinants of voltage-dependent inactivation affect mibefradil block of calcium channels. Neuropharmacol 2000;39:1-10
29. Eller P, Berjukov S, Wanner S. High affinity interaction of mibefradil with voltage-gated calcium and sodium channels. Br J Pharmacol 2000;130:669-77
30. Gomora JC, Enyeart JA, Enyeart JJ. Mibefradil potently blocks ATP-activated potassium channels in adrenal cells. Mol Pharmacol 1999;56:1192-7
31. Nilius B, Prenen J, Kamouchi M, et al. Inhibition by mibefradil, a novel calcium channel antagonist, of calcium and volume-activated chlorine channels in macrovascular endothelial cells. Br J Pharmacol 1997;121:547-55
32. Moosmang S, Haider N, Bruderl B, et al. Antihypertensiev effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2. Circ Res 2006;98:105-10
33. Huang L, Keyser BM, Tagmose TM, et al. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3- Benzimidazol-2-yl) propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1- isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 2004;309:193-9
34. Rimoli MG, Russo E, Cataldi M, et al. T-type channel blocking properties and antiabsence activity of two imidazo [1,2-b]pyridazine derivatives structurally related to indomethacin. Neuropharmacol 2009;56:637-46
35. Merck & Co., Inc. Enhancement of sleep with T-type calcium channel antagonists. WO2004035000
36. Merck & Co., Inc. Preparation of quinazoline derivatives as inhibitors of HIV reverse transcriptase. WO9304047; 1993
37. Merck & Co., Inc. Quinazolinone T-type calcium channel antagonists. WO2006098969; 2006
38. Barrow JC, Rittle KE, Reger TS, et al. Discovery of 4,4-disubstituted quinazolin-2-ones as T-type calcium channel antagonists. ACS Med Chem Lett 2010;1:75-9
39. Uebele VN, Nuss CE, Fox SV, et al. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys 2009;55:81-93
40. Merck & Co., Inc. Quinazolinone T-type calcium channel antagonists. WO2009009015; 2009
41. Schlegel K-AS, Yang Z-Q, Reger TS, et al. Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists. Bioorg Med Chem Lett 2010;20:5147-52
42. Merck & Co., Inc. 3-fluoro-piperidine T-type calcium channel antagonists. WO2007002361; 2007
43. Yang Z, Barrow JC, Shipe WD, et al. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem 2008;51:6471-7
44. Merck & Co., Inc. 4-fluoro-piperidine T-type calcium channel antagonists. WO2007002884; 2007
45. Shipe WD, Barrow JC, Yang Z, et al. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. J Med Chem 2008;51:3692-5
46. Merck & Co., Inc. Pyridyl amide T-type calcium channel antagonists. WO2007120729; 2007
47. Kraus LR, Li Y, Gregan Y, et al. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther 2010;335:409-17
48. Merck & Co., Inc. Pyrazinyl amide T-type calcium channel antagonists. WO2009054982; 2009
49. Merck & Co., Inc. Heterocyle amide T-type calcium channel antagonists. WO2009054983; 2009
50. Merck & Co., Inc. Heterocycle phenyl amide T-type calcium channel antagonists. WO2009054984; 2009
51. Yang ZQ, Schlegel KAS, Shu Y, et al. Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett 2010: published online 24 August 2010, doi: 10.1021/ml100170e
52. Neuromed pharmaceuticals. Di-t-butylphenyl piperazines as calcium channel blockers. US20090270413; 2009
53. Neuromed pharmaceuticals LTD. Amide derivatives as calcium channel blockers. WO2008110008; 2008
54. Neuromed pharmaceuticals LTD. 4-(Aminomethyl)cyclohexylamine derivatives as calcium channel blockers. WO2009146539; 2009
55. Neuromed pharmaceuticals LTD. N-Piperidinyl acetamide derivatives as calcium channel blockers. WO2009146540; 2009
56. Neuromed pharmaceuticals LTD. Bicyclic pyrimidine derivatives as calcium channel blockers. US20080280900; 2008
57. Bristol-Myers Squibb. Substituted dihydropyrimidine inhibitors of calcium channel function. WO2005007124; 2005
58. Bristol-Myers Squibb. Preparation of dihydropyrimidone derivatives as inhibitors of calcium channel function. WO2005009392; 2005
59. Hangeland JJ, Cheney DL, Friends TJ, et al. Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core. Bioorg Med Chem Lett 2008;18:474-8
60. Bristol-Myers Squibb. Preparation of sulfonyl amides as inhibitors of calcium channel function. US2005245535; 2005
61. Icagen. Preparation of [5-(3-ethoxybenzenesulfonyl)thiazol-2-yl]amine derivatives as calcium channel antagonists. WO2007073497; 2007
62. Icagen. Preparation of thiazoles as calcium channel antagonists. WO2007075852; 2007
63. Schering corporation. Azetidine and azetidinone derivatives useful in treating pain and disorders of lipid metabolism. WO2008033447; 2008
64. Schering corporation. Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism. WO2008033456; 2008
65. Schering corporation. Treating pain, diabetes and disorders of lipid metabolism. WO2008033460; 2008
66. Schering corporation. Azetidinone derivatives and methods of use thereof. WO2008033464; 2008
67. Schering corporation. Azetidinone derivatives and methods of use thereof. WO2008033465; 2008
68. Smith EM, Sorota S, Kim HM, et al. T-type calcium blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis. Bioorg Med Chem Lett 2010;20:4602-6
69. Pfizer Products, Inc. Oxadiazoles compounds as calcium channel antagonists. WO2008050200; 2008
70. Pfizer Products Inc. Substituted oxadiazole analogs as calcium channel antagonists. WO2008117148; 2008
71. Pfizer Products, Inc. 1,4-Dihydronaphtyridine derivatives. WO2009056934; 2009
72. Abbott. Novel benzenesulfonamides as calcium channel blockers. WO2010083264; 2010
73. Korea Institute of Science and Technology. Preparation of 3,4-dihydroquinazolines as T-type calcium channel blockers. EP1568695
74. Lee YS, Lee BH, Park SJ, et al. 3,4-Dihydroquinazolines derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett 2004;14:3379-84
75. Rhim H, Lee YS, Park SJ, et al. Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett 2005;15:283-6
76. Park SJ, Park SJ, Lee MJ, et al. Synthesis and SAR studies of a novel series of T-type calcium channel blockers. Bioorg Med Chem 2006;14:3502-11
77. Jeong JA, Cho H, Jung SY, et al. 3D QSAR studies on 3,4- dihydroquinazolines as T-type calcium channel blocker by comparative molecular similarity indices analysis (CoMSIA). Bioorg Med Chem Lett 2010;20:38-41
78. Lee JY, Park SJ, Park SJ, et al. Growth inhibition of human cancer cells in vitro by T-type calclium channel blockers. Bioorg Med Chem Lett 2006;16:5014-17
79. Jung SY, Lee SH, Kang HB, et al. Antitumor activity of 3,4-dihydroquinazoline dihydrochloride in A549 xenograft nude mice. Bioorg Med Chem Lett 2010;20:6633-6
80. Korea Institute of Science and Technology. 2,4-quinazoline derivatives having activity to T-type calcium channel and preparation method thereof. WO2008007835, KR749843 Korea Institute of Science and Technology. 3-(4-Chloro-benzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-quinazoline derivative as T-type calcium channel antagonists. KR754325
81. Korea Institute of Science and Technology. 1,3-dioxoisoindole derivatives having selective antagonism of T-type calcium channel. US7319098; 2007
82. Korea Institute of Science and Technology. Novel isoindolinone derivatives having inhibitory activity against T-type calcium channel and method for preparation thereof. US20100004286; 2010
83. Jo MN, Seo HJ, Kim Y, et al. Novel T-type calcium channel blockers: Dioxoquinazoline carboxamide derivatives. Bioorg Med Chem 2007;15:365-73
84. Kim HS, Kim Y, Doddareddy MR, et al. Design, synthesis, and biological activity of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers. Bioorg Med Chem Lett 2007;17:476-81
85. Jung HK, Doddareddy MR, Cha JH, et al. Synthesis and biological evaluation of novel T-type Ca2+ channel blockers. Bioorg Med Chem 2004;12:3965-70
86. Korea Institute of Science and Technology. Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof. EP1757590
87. Korea Institute of Science and Technology. Preparation of pyrazolylcarboxamidoalkyl piperazine derivatives as T-type calcium ion channel antagonists. KR2009044924; 2009
88. Korea Institute of Science and Technology. Novel pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof. US2010094006; 2010
89. EWHA University-Industry Collaboration Foundation. Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain. WO2009035307; 2009
90. Korea Institute of Science and Technology. Novel imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation methods thereof. US20090325979; 2009
91. Kam YL, Rhee H-K, Rhim H, et al. Synthesis and T-type calcium channel activity of novel diphenylpiperazin compounds, and evaluation of in vivo analgesic activity. Bioorg Med Chem 2010;18:5938-44
92. Korea Institute of Science and Technology. Composition containing morpholin-2-one derivatives for blocking T-type calcium channel, for prevention and treatment of myocardial disease, pain, heart attack, hypertension, and epilepsy. KR758317; 2007
93. Ku IW, Cho S, Doddareddy MR, et al. Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett 2006;16:5244-8
94. Korea Institute of Science and Technology. Novel thiazole-based compound and inhibitor of T-type calcium channel containing the same. WO2008018655; 2008
95. Korea Institute of Science and Technology. Novel 2-imino-1,3-thiazoline- based compounds and T-type calcium channel inhibitors containing the same. US20080293786, KR2010063329; 2008
96. Han M, Nam KD, Shin D, et al. Exploration of novel 2-alkylimino-1, 3-thiazolines: T-type calcium channel inhibitory activity. J Comb Chem 2010;12:518-30
97. Korea Institute of Science and Technology. Novel phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of T-type calcium channel containing the same as an active ingredient. US20100056545; 2010
98. Lee HK, Lee YS, Roh EJ, et al. Synthesis and evaluation of alpha,alpha¢-disubstituted phenylacetate derivatives for T-type calcium channel blockers. Bioorg Med Chem Lett 2008;18:4424-7
99. University of Virginia. Inhibiting CaV3 isoforms and the delta 25B splice variants for the diagnosis and treatment of cancer. WO2005077082; 2005
100. University of Virginia. T-type calcium channel blockers and the treatment of diseases. WO2006023881
101. University of Virginia. T-type calcium channel inhibitors. WO2006023883; 2006
102. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90
103. Zalicus Pipeline: focused on pain and inflammation. Available from: http://www.combinatorx.com/product-pipeline/pipeline-overview.asp [Last accessed 27 October 2010]